RESEARCHER PROFILE

Peter James O'Dwyer

← Back to University of Pennsylvania

P

University of Pennsylvania

Cancer Genomics and DiagnosticsColorectal Cancer Treatments and StudiesLung Cancer Treatments and MutationsPancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Peter James O'Dwyer works in Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, Pancreatic and Hepatic Oncology Research, Cancer Immunotherapy and Biomarkers. Recorded institutional associations include ECOG-ACRIN Cancer Research Group, Abramson Cancer Center, University of Pennsylvania.

822Publications
43,318Citations
89H-index

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    2016 · 5,856 citations

  2. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

    2010 · 3,561 citations

  3. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

    2007 · 2,282 citations

  4. CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

    2011 · 1,672 citations

  5. Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy

    2014 · 1,149 citations

  6. Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

    2006 · 1,032 citations

  7. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer

    2015 · 695 citations

  8. Phase II Trial of Sorafenib in Advanced Thyroid Cancer

    2008 · 680 citations

  9. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

    2006 · 644 citations

  10. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer

    2018 · 588 citations

  11. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

    2012 · 546 citations

  12. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

    2014 · 515 citations

  13. Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody

    2007 · 513 citations

  14. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

    2015 · 482 citations

  15. A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

    2013 · 456 citations

  16. Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

    2010 · 446 citations

  17. Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

    2009 · 438 citations

  18. Combined MTOR and autophagy inhibition

    2014 · 424 citations

  19. Combined-Modality Treatment for Resectable Metastatic Colorectal Carcinoma to the Liver: Surgical Resection of Hepatic Metastases in Combination With Continuous Infusion of Chemotherapy--An Intergroup Study

    2002 · 421 citations

  20. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

    2014 · 367 citations

  21. Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

    2011 · 365 citations

  22. Etoposide (VP-16–213)

    1985 · 358 citations

  23. CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment

    2014 · 343 citations

  24. Gene Expression Patterns in Ovarian Carcinomas

    2003 · 327 citations

  25. Mechanisms of Hypertension Associated With BAY 43-9006

    2006 · 324 citations

← Return to the university profile